AIM:To evaluate the effect ofβ-catenin immunohistochemical expression on the prognosis of gastric cancer(GC).METHODS:We searched Pubmed and Embase to identify eligible studies.The search ended on November 10,2013,with no lower date limit.The citation lists associated with the studies were used to identify additional eligible studies.We included studies reporting sufficient information to estimate the HR and 95%CI,and information to estimate the OR in the analysis of clinicopathological features.The qualities of these studies were assessed using the Newcastle-Ottawa Quality Assessment Scale.HRs and ORs and their variance were calculated and pooled using Review Manager Version 5.2.RESULTS:A total of 24 studies were identified and comprised 3404 cases.β-catenin expression was significantly correlated with poor overall survival(OS)in GC patients(HR=1.85,95%CI:1.39-2.46),but showed a significant degree of heterogeneity(I2=71%,P<0.0001).Subgroup analysis indicated that an abnormal pattern ofβ-catenin expression had an unfavorable effect on OS(HR=1.79,95%CI:1.39-2.32).However,accumulation in the nucleus or loss of membrane did not influence the survival of GC patients independently.Moreover,the combined OR ofβ-catenin indicated thatβ-catenin expression was associated with Lauren classification(OR=1.98,95%CI:1.19-3.29),lymph node metastasis(OR=2.00,95%CI:1.44-2.77),distant metastasis(OR=2.69,95%CI:1.35-5.38)and grade of differentiation(OR=2.68,95%CI:1.66-4.34).β-catenin expression did not correlate with TNM stage(OR=1.34 95%CI:0.96-1.86),the depth of invasion(OR=1.48,95%CI:0.94-2.33)or vascular invasion(OR=1.11,95%CI:0.70-1.76).CONCLUSION:Abnormalβ-catenin immunohistochemical expression may be associated with tumor progression and could be a predictive factor of poor prognosis in patients with GC. AIM: To evaluate the effect of β-catenin immunohistochemical expression on the prognosis of gastric cancer (GC). METHODS: We searched Pubmed and Embase to identify eligible studies. Search on November 10, 2013, with no lower date limit. The citation lists associated with the studies were used to identify additional eligible studies. We included studies reporting sufficient information to estimate the HR and 95% CI, and information to estimate the OR in the analysis of clinicopathological features. qualities of these studies were assess using the Newcastle-Ottawa Quality Assessment Scale. HRs and ORs and their variance were calculated and pooled using Review Manager Version 5.2.RESULTS: A total of 24 studies were identified and comprised 3404 cases. Β-catenin expression was significantly correlated with poor overall survival (OS ) in GC patients (HR = 1.85, 95% CI: 1.39-2.46), but showed a significant degree of heterogeneity (I2 = 71%, P <0.0001) of β-catenin expression had an unfavorable effect on OS (HR = 1.79, 95% CI: 1.39-2.32) .Wowever, accumulation in the nucleus or loss of membrane did not influence the survival of GC patients independently. Moreover, the combined OR ofβ -catenin showed that β-catenin expression was associated with Lauren classification (OR = 1.98,95% CI: 1.19-3.29), lymph node metastasis (OR = 2.00,95% CI: 1.44-2.77), distant metastasis 95% CI: 1.35-5.38) and grade of differentiation (OR = 2.68, 95% CI: 1.66-4.34). The β-catenin expression did not correlate with TNM stage (OR = 1.34 95% CI: 0.96-1.86), the depth of invasion (OR = 1.48, 95% CI: 0.94-2.33) or vascular invasion (OR = 1.11, 95% CI: 0.70-1.76) .CONCLUSION: Abnormal beta-catenin immunohistochemical expression may be associated with tumor progression and could be a predictive factor of poor prognosis in patients with GC.